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we report the first case of HP after EBV treatment. Our find-
ing of in vitro release of nickel ions from EBVs may contribute 
to the current understanding on hypersensitivity reactions 
after nitinol implants in patients with nickel contact allergy. 
However, it did not confirm a causative relationship. 
 © 2017 S. Karger AG, Basel 
 Introduction 
 Bronchoscopic lung volume reduction (BLVR) with 
endobronchial valves (EBVs) has been shown to improve 
pulmonary function and exercise capacity in patients 
with severe emphysema  [1–3] . EBVs are 1-way valves 
which are implanted bronchoscopically into the segmen-
tal bronchi, disabling airflow to a target region of the dis-
eased lung, and allowing trapped air to escape. Eventu-
ally, the lung volume reduction effect is achieved by lobar 
atelectasis to reduce hyperinflation  [4] . There are 2 types 
of EBV, both consisting of a frame made of nitinol, a met-
al alloy of nickel and titanium, which is covered by a sili-
cone membrane. Due to its unique combination of shape 
memory, elasticity properties, and biocompatibility re-
sponse, nitinol is widely used in medicine for orthodontic 
arch wires, filters, stents, bone anchors, and EBVs  [5] . 
 Keywords 
 Bronchoscopic lung volume reduction · Endobronchial 
valves · Nickel contact allergy · Nickel release · 
Hypersensitivity pneumonitis  
 Abstract 
 Background: Endobronchial valve (EBV) placement is an es-
tablished lung volume reduction procedure aiming to im-
prove lung function and exercise capacity in patients with 
severe emphysema. As EBVs consist of silicone and nitinol (a 
metal alloy of nickel and titanium), there are concerns that 
nickel ions might be released and could have a clinical im-
pact in patients with a contact allergy to nickel. Based on a 
case with hypersensitivity pneumonitis (HP) after treatment 
with EBVs, we aimed to evaluate the in vitro nickel release 
from EBVs using inductively coupled plasma mass spectrom-
etry (ICP-MS) and scanning electron microscopy (SEM). 
 Methods: Six EBVs were immersed in artificial saliva for a pe-
riod of 7 days. At 24-h intervals, the nickel ion concentration 
was measured using ICP-MS.  Results: There was evidence of 
a significant nickel release from EBV during the first 48 h, 
which is possibly due to an incomplete silicone layer detect-
ed by SEM. The concentration of released nickel was below 
the toxic limit.  Conclusions: To the best of our knowledge, 
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Formally, EBVs are contraindicated in patients with 
known allergies to nitinol or silicone  [6] . In addition, 
there is controversy regarding the effects of nickel alloy-
based device implantation in patients with nickel contact 
allergy, since there is concern about the release of nickel 
after nitinol device implantation  [7, 8] .
 To the best of our knowledge, a case of hypersensitiv-
ity pneumonitis (HP) after treatment with EBVs in a pa-
tient with nickel allergy has not yet been reported. Based 
on this case, we aimed to evaluate the in vitro nickel re-
lease from EBVs using inductively coupled plasma mass 
spectrometry (ICP-MS) and scanning electron micros-
copy (SEM).
 Methods 
 Two new (2 × 4.0 mm) and 4 used EBVs (2 × 4.0mm and 2 × 
5.5 mm, Zephyr ® , PulmonX International Sàrl, Neuchâtel, Swit-
zerland) were evaluated with SEM and ICP-MS. The used EBVs 
had been explanted from another patient due to collateral ventila-
tion after an inbody period of 2 months. All measurements were 
performed at The Laboratory of Central Switzerland, Brunnen 
(Lab 1) and The Zurich University of Applied Sciences, Wädenswil 
(Lab 2), Switzerland.
 Inductively Coupled Plasma Mass Spectrometry 
 All 6 EBVs were immersed and shaken (shaking frequency 100 
times/min) in 3 mL of artificial saliva (Glandosane ® , Helvepharm 
AG, Frauenfeld, Switzerland) at 37  °  C for a period of 7 days in Lab 
1. One gram of Glandosane consists of: Kalii chloridum 1.2 mg, 
Natrii chloridum 844 μg, Magnesii chloridum 52 μg, Calcii chlori-
dum 146 μg, Dikalii phosphas anhydricus 342 μg, Carboxymeth-
ylcellulosum natricum 10 mg, and Sorbitolum 30 mg. At 24-h in-
tervals, 2 mL of the solution was extracted and 1: 1 replaced by fresh 
Glandosane. The nickel content of the extracted test solution was 
measured using the ELAN ® DRC-e ICP-MS (Perkin-Elmer, 
Waltham, MA, USA) with a cross-flow nebulizer. 
 Scanning Electron Microscopy 
 SEM images of EBV surfaces were captured using a Quanta 
FEG 250 microscope (FEI, Hillsboro, OR, USA) with a low vacuum 
(1.5-mbar) and without conductive coating before and after im-
mersion in artificial saliva at the positions indicated in  Figure 1 . 
SEM imaging was performed in 2 independent laboratories to ex-
clude handling failure. For this, a second set of 1 explanted (4.0 
mm) and 1 new valve (4.0 mm) was analyzed in Lab 2 (SEM only). 
 Results 
 Clinical Case Report 
 A 53-year-old previous smoker (40 pack-years) with 
severe emphysema was referred for evaluation of BLVR, 
as his dyspnea and exercise capacity had worsened over 
the last months. Once a year, he suffered from acute ex-
acerbations of chronic obstructive pulmonary disease 
(AECOPD), with the last episode being a year ago. His 
baseline pulmonary function test values are displayed in 
 Table 1 . Chest computed tomography (CCT;  Fig. 2 a, b) 
and lung perfusion scintigraphy revealed homogeneous 
emphysema with impaired perfusion of both upper zones. 
His medical history was otherwise uneventful, except for 
acute intermittent porphyria and an allergy to nickel. The 
latter had been confirmed by a patch test some years ear-
lier. His medication comprised inhalational tiotropium 
and formoterol/budenoside, and long-term oxygen ther-
apy (1–2 L/min). He had completed an ambulatory pul-
monary rehabilitation program, but there was no distinct 
benefit concerning his symptoms. Since the patient de-
clined surgical lung volume reduction, a decision was 
made to perform BLVR with EBVs for bridging to lung 
transplantation. Due to his nickel allergy, EBVs were pre-
ferred to coils, since the latter are not covered by a silicone 
layer, allowing nitinol to be in direct contact with the 
bronchial mucosa. After exclusion of collateral ventila-
tion with the Chartis ® technology (PulmonX Interna-
tional Sàrl)  [9] , 4 EBVs (Zephyr) were implanted bron-
choscopically in the right upper lobe (4.0-mm valves in 
segments B3a and B3b, and 5.5-mm valves in segments 
B1 and B2). The postinterventional course was unevent-
ful, and the patient was discharged on the third day af-
ter implantation. A month later, he reported worsening 
cough, increasing dyspnea, and a new itching exanthema 
on his trunk and face. There was no change in concurrent 
medication. Since AECOPD was suspected, a course of 
Position A
Position B
Position C
 Fig. 1. An endobronchial valve (Pulmonx Sarl, Neuchâtel, Switzer-
land) showing the positioning of the scanning electron microscopy 
images. 
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prednisolone (20 mg/day over 7 days) was given, result-
ing in temporary improvement of these symptoms, but 
they returned 2 weeks later, this time with a new onset of 
fever (up to 39.0   °   C) and chills. Laboratory parameters 
revealed normal counts of leukocytes, neutrophils, mono-
cytes, lymphocytes, and eosinophils, increased C-reactive 
protein (97 mg/L), and normal procalcitonin (0.05 μg/L). 
Pulmonary function testing ( Table 1 ) was notable for the 
decline of the diffusion capacity of the lung for carbon 
monoxide (DLCO), although the FEV 1 had improved by 
160 mL, and residual volume was reduced by 480 mL. 
CCT ( Fig. 2 c, d) was performed, revealing complete right 
upper-lobe atelectasis after the EBV treatment, but there 
was marked ground-glass opacification of all other lobes 
with the beginning of consolidation in the left lower lobe. 
After bronchoscopy including bronchoalveolar lavage 
 Table 1.  Pulmonary function test values before and after bronchoscopic lung volume reduction with endobronchial valves in the right 
upper lobe
Baseline FU at 1 month FU at 3 months
(50 mg PDN)
FU at 4 months 
(20 mg PDN)
FU at 6 months 
(12.5 mg PDN)
FVC, L 2.43 (60) 2.33 (55) 2.61 (65) 3.18 (79) 2.52 (62)
FEV1, L 1.08 (33) 1.24 (37) 1.23 (38) 1.22 (37) 1.15 (35)
TLC, L 6.97 (107) 6.84 (101) n.a. n.a. 6.93 (107)
RV, L 5.01 (229) 4.49 (202) n.a. n.a. 3.75 (172)
RV/TLC, % 72 66 n.a. n.a. 54
DLCO, mmol/min/kPA 4.86 (52) 4.05 (42) 4.53 (49) 5.32 (57) 6.57 (71)
6-MWT, m 356 n.a. n.a. n.a. 330
MRC dyspnea scale 4 5 3 3 3
Cough + +++ ++ ++ +
 Percentage predicted values appear in parentheses. DLCO, carbon monoxide diffusing capacity of the lung; FEV1, forced expiratory 
volume in 1 s; FU, follow-up; FVC, forced vital capacity; MRC, Medical Research Council; 6-MWT, 6-min walking test; PDN, pred-
nisolone; TLC, total lung capacity, RV, residual volume; n.a., not available.
a
b
c
d
 Fig. 2. Chest computed tomography (CT) 
before and 1 month after bronchoscopic 
lung volume reduction with endobronchial 
valves (EBVs).  a ,  b Transverse chest CT 
images of the upper and lower zone (lung 
window) showing centroacinar pulmonary 
emphysema, but otherwise unremarkable 
lung parenchyma (no signs of interstitial 
lung disease, or ground-glass opacities) be-
fore EBV treatment.  c ,  d Corresponding 
CT images revealing atelectasis of the right 
upper lobe after treatment with EBV. In ad-
dition, ground-glass opacification in the 
bilateral upper and lower lobes, turning 
into consolidation in the left lower lobe.  
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(BAL), an infectious cause for the patient’s deterioration 
was excluded, since there was no evidence of (myco)bac-
terial, fungal, or viral pathogens. HP was suspected, since 
there was marked BAL lymphocytosis (57% lympho-
cytes) with a CD4/CD8 coefficient of 2.6, and slight BAL 
eosinophilia (6% eosinophils). There was no increase of 
BAL neutrophils (2%). However, no IgE-mediated sensi-
tizations to common inhalant allergens or molds could be 
detected (Sx1 and Rx2), and the total IgE was in the nor-
mal range (99 kU/L). There was no evidence of an inha-
lational antigen in the patient’s history, since he denied 
exposure to an air humidifier, animals, or mold. Exten-
sive patch testing could only reveal a strong skin reaction 
to nickel, but was negative for other possible antigens. 
Notably, EBVs with and without the silicone jacket (i.e., 
the nitinol frame only) did not provoke any skin reaction. 
Assuming a pulmonary and systemic hypersensitivity re-
action to nickel, oral prednisolone (50 mg/day) was re-
started, and the symptoms improved gradually. DLCO 
exceeded the baseline values over the following months 
( Table  1 ). Prednisolone could thus be tapered slowly, 
with no recurrence of the symptoms.
 In vitro Evaluation 
 Compared to days 3–7 and to blank artificial saliva, 
there was a significantly increased nickel content in the 
extracted test solution after 24 and 48 h, respectively ( Ta-
ble 2 ). 
 The SEM images of EBVs before and after immersion 
in the artificial saliva are displayed in  Figure 3 . In the new 
EBVs, there was evidence of an incomplete silicone layer 
which had an imbricate surface ( Fig. 3 a). In the explanted 
EBVs, the silicone-free areas were larger than in the new 
EBVs ( Fig. 3 c) and the imbricate surface was only mar-
 Table 2.  Nickel content in artificial saliva (Glandosane) after im-
mersion of the endobronchial valves
 Total nickel release, μg/L
da y 1 day 2 days 3 – 7
New EBVs
1 (4.0 mm) 3.7 0.6 *
2 (4.0 mm) 7.5 1.4 *
Explanted EBVs
1 (4.0 mm) 11.9 0.7 *
2 (4.0 mm) 21.5 3.2 *
3 (5.5 mm) 9.6 1.4 *
4 (5.5 mm) 16.9 2.7 *
 Values show the results of individual measurements. * These 
values did not differ from the nickel concentration in the artificial 
saliva. EBVs were immersed and shaken (shaking frequency 100 
times/min) in 3 ml of artificial saliva at 37° C for a period of 7 days. 
At 24-h intervals, 2 ml of the solution was extracted and 1:1 re-
placed with fresh solution. The nickel content of the extracted test 
solution was measured using the ELAN DRC-e ICP-MS with a 
cross-flow nebulizer. EBV, endobronchial valve.
a b
c d
 Fig. 3. Scanning electron microscopy im-
ages of the endobronchial valves (EBVs). 
All pictures were captured at position A in 
 Figure 1 .  a A new EBV before immersion 
in artificial saliva.  b A new EBV after im-
mersion in artificial saliva.  c An explanted 
EBV before immersion.  d An explanted 
EBV after immersion. ×1,000. 
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ginally visible. Silicone-free areas were larger after abra-
sion and immersion in artificial saliva ( Fig. 3 b). More-
over, there was evidence of delamination of the silicone 
layer from the nitinol wire ( Fig. 3 d).
 Discussion 
 Systemic hypersensitivity syndromes due to surgical 
implants are well known  [10–12] . However, this is the 
first report describing HP after BLVR with EBVs in a pa-
tient with a proven contact allergy to nickel. For different 
reasons, this case is highly informative, and raises impor-
tant questions regarding the clinical relevance of nitinol 
devices in patients with nickel allergy. Above all, nickel 
contact allergy occurs in up to 19% of the population and 
is the most frequent cause of allergic contact dermatitis 
 [13] . 
 Due to its physical properties, nitinol is an ideal metal 
alloy for various implantable devices  [5] . However, dif-
ferent types of hypersensitivity reactions including se-
vere bronchospasm after nitinol device implantation 
have been reported  [14–19] . The systemic reaction to 
nickel was described 25 years ago as Kounis syndrome, 
i.e., concurrent chest discomfort, dyspnea, faintness, 
nausea, vomiting, syncope, pruritus, urticaria, hypoten-
sion, diaphoresis, pallor, palpitations, and bradycardia, 
with conditions associated with mast cell activation in-
cluding allergic, hypersensitive, anaphylactic, or anaphy-
lactoid insult  [20, 21] . Thus, there is considerable con-
cern about the release of nickel after nitinol device im-
plantation  [7] .
 Using ICP-MS, Nayak et al.  [22]  recently demonstrat-
ed a statistically significant increase of 10.35 ppb in the 
nickel ion concentration in the saliva of 30 patients after 
orthodontic aligning of nitinol arch wires. Shabalovskaya 
et al.  [23, 24]  reported that nickel release from nitinol is 
10- to 16-times greater than that from stainless steel dur-
ing the first day of immersion in cell cultures, decreasing 
to the level of stainless steel by the third day of immersion. 
Therefore, attempts have been undertaken to prevent 
nickel release, e.g., a nanoplatinum coating or a silicone 
layer in nitinol devices  [25] . In addition, for patients with 
a positive history to nickel allergy, patch testing is thought 
to be necessary prior to nitinol device implantation to 
rule out nickel contact allergy-related complications. 
However, in the study of Kim et al. [8] , positive reactions 
to nickel in a patch test were not associated with adverse 
outcomes following closure of atrial septal defects with a 
nickel alloy-based device. 
 Interestingly, our patient showed a strong reaction in 
the nickel patch test, but not to the nitinol-containing 
EBV. We hypothesize, therefore, that there must be a re-
lease of nickel from the EBV when in contact with the 
bronchial mucosa, which could possibly result in a hyper-
sensitivity reaction. It is also possible that the patch test 
with EBV was too short to release the critical amount of 
nickel molecules.
 In line with the findings published by Nayak et al.  [22] , 
we found in vitro evidence of nickel release from EBVs 
after immersion in artificial saliva, i.e., imitating the bron-
chial environment. The question as to how nickel ions 
find their way through the silicone layer covering the 
EBVs is apparently answered by SEM images. In both the 
new and explanted EBVs, we found an incomplete silicone 
layer, enabling the nitinol wire to be in direct contact with 
the bronchial mucosa. The reasons for this incomplete sil-
icone layer are unknown. A handling failure during SEM 
seems unlikely, since the findings were confirmed by an 
independent laboratory. The SEM images showed that the 
assembly process of the valves on the SEM microscope was 
likely not responsible for the silicone-free zones of the 
valves. A second unanswered question is why the used 
valves showed a similar nickel release to that of the new 
ones, even though this was only detectable during the first 
48 h. The explanted valves should have ended their nickel 
release during the first 48 h after their initial implantation, 
which had been performed months before explantation.
 The concentration of released nickel exceeded the tox-
ic limit of 20 μg/kg per day in only 1 measurement. How-
ever, this toxicity reference value is based on postimplan-
tation loss/perinatal mortality derived from animal stud-
ies in rats  [26] . In patients with nickel contact allergy, the 
release of nickel is of concern as it may lead to a hypersen-
sitivity reaction. A particular toxicity reference value of 
4 μg/kg for nickel-sensitized patients was thus proposed, 
based on the study of single exposures in humans  [26] .
 According to our investigations, the nickel release was 
measurable solely during the first 48 h after the immer-
sion in artificial saliva. This could be the reason that the 
hypersensitivity reaction in our patient was temporary, 
even though the EBVs were not removed and the cortico-
steroids could be tapered without the recurrence of symp-
toms. Additionally, there could have been a tolerance ef-
fect over time. However, likely following a different 
pathophysiological pathway, pneumonitis has been re-
ported after exposure to nickel fumes  [27] .
 Our study has a major limitation, which is due to the 
case report of only 1 subject and the small sample of EBVs 
investigated. It also remains unknown whether our ex-
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perimental set-up is comparable to in vivo conditions, so 
we cannot say if the damage to the silicone layer or the 
release of nickel was possibly due to the experimental set-
up. Furthermore, it remains unproven that the reported 
HP was actually due to nickel hyperreactivity. Admitted-
ly, we did not perform a rigorous blood test of common 
HP triggers, since the patient denied having had any cor-
responding exposures. Nevertheless, the findings are 
unique and relevant for the understanding of the biolog-
ical behavior of nitinol in contact with human tissue.
 Conclusions 
 Although this is only the first case of HP after EBV treat-
ment and no causative relationship was confirmed, our 
finding of an in vitro release of nickel ions may contribute 
to the current knowledge on hypersensitivity reactions af-
ter nitinol implants in patients with nickel contact allergy. 
The growing number of reported hypersensitivity reactions 
to nitinol, with its widespread applications in various med-
ical implants including airway stents and valves, justifies 
further in vitro and in vivo studies to confirm our findings. 
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